Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. director Adam Leo Stone received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no cost as a compensation grant.
The option grant vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the company’s next annual stockholder meeting after that date. Any unvested portion will vest automatically upon specified change in control events, and the options expire on June 10, 2036.
Solid Biosciences Inc. reported the results of its Annual Meeting of Stockholders. Shareholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 240,000,000 to 480,000,000 shares.
They elected three Class II directors, Clare Kahn, Adam Stone and Lynne Sullivan, to serve until the 2029 annual meeting. Stockholders also ratified, on an advisory basis, Ilan Ganot as a Class I director through the 2028 meeting and confirmed PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
In addition, shareholders approved a non-binding advisory vote on executive compensation. Most proposals received strong support, with the share increase amendment passing with 85,604,508 votes for, 893,360 against and 27,502 abstaining.
SLDB files a prospectus supplement updating its list of selling stockholders. The supplement states the aggregate number of shares registered remains the same and replaces the prior selling‑stockholder table with updated holdings as of May 15, 2026. The supplement cites 98,449,606 shares outstanding as of May 15, 2026 used to calculate percentages.
The table shows multiple large holders with updated "Number of Shares Being Offered" and resulting post‑offering percentages; the prospectus supplement is to be read together with the March 31, 2026 prospectus.
Solid Biosciences reported a larger quarterly loss as it ramped investment in its gene therapy pipeline. For the three months ended March 31, 2026, net loss was $56.7 million compared with $39.3 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $46.1 million from $30.9 million, reflecting manufacturing and clinical costs for lead Duchenne candidate SGT‑003 and increased activity in SGT‑212 for Friedreich’s ataxia. General and administrative expenses increased to $11.2 million from $9.1 million.
The company strengthened its balance sheet through a March 2026 private placement and at‑the‑market sales, lifting total assets to $422.9 million and stockholders’ equity to $374.1 million as of March 31, 2026. Cash, cash equivalents and available‑for‑sale securities were $380.7 million, which management expects will fund operations into the first half of 2028.
Solid Biosciences Inc. ownership filing: Reporting persons led by Invus Public Equities and affiliated entities report collective beneficial ownership of 10,066,682 shares, equal to 9.99% of issued and outstanding common stock as of March 31, 2026.
The total consists of 7,690,405 Shares and 2,376,277 Warrants exercisable one-for-one; calculations use 98,391,314 Shares outstanding as of March 16, 2026. The Warrants contain a Beneficial Ownership Limitation that prevents exercise that would raise ownership above 9.99% (changeable by a holder upon 61 days' notice).
BlackRock, Inc. reports beneficial ownership of 4,578,650 shares (4.7%) of Solid Biosciences Inc. common stock as of 03/31/2026. The filing (Schedule 13G/A, CUSIP 83422E204) shows sole voting power of 4,515,473 and sole dispositive power of 4,578,650. The amendment was signed on 04/27/2026 by Spencer Fleming, Managing Director.
Solid Biosciences Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 10, 2026. The company seeks to elect three Class II directors to terms ending in 2029 and ratify the advisory appointment of co‑founder Ilan Ganot as a Class I director through 2028.
Stockholders are also asked to ratify PricewaterhouseCoopers LLP as auditor for 2026, approve an amendment doubling authorized common stock from 240,000,000 to 480,000,000, and cast an advisory “say‑on‑pay” vote on executive compensation. The record date is April 16, 2026, with 98,413,277 common shares entitled to one vote each.
Howton David T reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. reported that Chief Operating Officer David T. Howton received a grant of 79,341 restricted stock units (RSUs), each representing a contingent right to one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, where 25% of the target RSUs vest upon each of four predetermined performance milestones.
The Board determined that the second performance milestone was met on January 29, 2026, triggering this portion of the award. The shares tied to this milestone are scheduled to vest in the first quarter of 2027, subject to Mr. Howton’s continued service with the company on the evaluation date. This is a compensation-related equity award, not an open-market stock purchase.
Brooks Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. Chief Medical Officer Brooks Gabriel reported an award of 58,847 restricted stock units (RSUs) tied to performance stock units. Each RSU represents a right to receive one share of common stock as it vests. These RSUs relate to the second of four performance milestones under PSUs originally granted on June 11, 2024.
The Board determined that the performance criteria for the second milestone were met on January 29, 2026. The associated RSUs will vest only if Gabriel continues to serve the company through the Evaluation Date, which is anticipated to occur in the first quarter of 2027.